Table 1 Patient demographics and outcomes
From: Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny
Patient study number | Sex (M/F) | Ethnicity | Age | Type of Cancer | Prior Treatments | Active Disease Sites | Stage | Evidence of transient tumor response | Response at day 60 | PFS (mo) | OS (mo) | Sites of Progression | Post-Study Treatments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NYSCT-01 | M | Hispanic | 25 | Epitheloid Sarcoma | Pazopanib | Right forearm; right humerus; pulmonary nodules | IV | No | PD | 2 | 20 | Liver | Trabectedin, pazopanib |
NYSCT-02 | F | Caucasian | 21 | Synovial Sarcoma | Radiation; doxorubicin+ifosfamide; enoblituzumab+doxorubicin; high-dose ifosfamide; anlotinib; regorafanib | Right chest wall; pulmonary nodules | IV | NA (did not ultimately receive treatment/ withdrew from study) | NA | NA | NA | NA | NA |
NYSCT-03 | F | Caucasian | 28 | Synovial Sarcoma | Surgery; Radiation; doxorubicin+ifosfamide; olaratumab+doxorubicin; gemcitabine+doxetaxel; pazopanib | Right thigh; pulmonary nodules | IV | Yes by PET/CT | PR | 2.5 | 2.5 | NA | NA |
NYSCT-04 | M | Hispanic | 56 | Synovial Sarcoma | Radiation; Doxorubicin+ifosfamide; high-dose ifosfamide; anlotinib; gemcitabine+docetaxel +ADI-PEG20; Trabectedin+nivolumab+T-VEC | Right hand; pulmonary nodules | III | NA (did not ultimately receive treatment/ withdrew from study) | NA | NA | NA | Left pectoralis mass | Ifosfamide, nivolumab, Yondelis |
NYSCT-05 | M | Caucasian | 38 | Synovial Sarcoma | Doxorubicin+ifosfamide; anlotinib | Right popliteal fossa; Lung | IV | Yes by PET/CT | SD | 2 | 10 | Intrathoracic LN and pulmonary nodules | INY |
